Report cover image

Anticoagulant Reversal Drugs Market by Product (Andexxa, Idarucizumab, Protamine), Distribution (Hospital Pharmacies, Retail Pharmacies) - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 192 Pages
SKU # IRE18418397

Description

Anticoagulant Reversal Drugs Market by Product (Andexxa, Idarucizumab, Protamine), Distribution (Hospital Pharmacies, Retail Pharmacies) - Global Forecast 2024-2030


The Anticoagulant Reversal Drugs Market size was estimated at USD 646.38 million in 2023 and expected to reach USD 725.40 million in 2024, at a CAGR 12.31% to reach USD 1,457.59 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anticoagulant Reversal Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anticoagulant Reversal Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anticoagulant Reversal Drugs Market, highlighting leading vendors and their innovative profiles. These include Alexion Pharmaceuticals Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., AstraZeneca PLC, Bausch Health Companies, Inc., BioVascular Inc., Boehringer Ingelheim GmbH, Cadila Healthcare Limited, CSL Limited, Daiichi Sankyo Company, Limited, Dr Reddy’s Laboratories Ltd,, Eli Lilly and Company, Fresenius Kabi AG, Genentech, Inc., Hikma Pharmaceuticals PLC, Octapharma AG, Otsuka Pharmaceutical Co., Ltd., and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the Anticoagulant Reversal Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product

Andexxa
  • Idarucizumab
  • Protamine
  • Tranexamic Acid
  • Vitamin K
  • Distribution

    Hospital Pharmacies
  • Retail Pharmacies
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Anticoagulant Reversal Drugs Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anticoagulant Reversal Drugs Market?
    3. What are the technology trends and regulatory frameworks in the Anticoagulant Reversal Drugs Market?
    4. What is the market share of the leading vendors in the Anticoagulant Reversal Drugs Market?
    5. Which modes and strategic moves are suitable for entering the Anticoagulant Reversal Drugs Market?


    Note: PDF & Excel + Online Access - 1 Year

    • Table of Contents

    192 Pages
    1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Anticoagulant Reversal Drugs Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Increasing prevalence of bleeding disorders and anticoagulant therapies
    5.1.1.2. Growing number of product approvals worldwide
    5.1.1.3. Increasing incidence of unplanned surgeries
    5.1.2. Restraints
    5.1.2.1. High cost of the patent drugs
    5.1.3. Opportunities
    5.1.3.1. Improvements in reimbursement policies globally
    5.1.3.2. Ongoing research activities and funding to treat anticoagulant-related bleeds
    5.1.4. Challenges
    5.1.4.1. Stringent regulatory reforms due to severe risks associated with the reversal of anticoagulation
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Anticoagulant Reversal Drugs Market, by Product
    6.1. Introduction
    6.2. Andexxa
    6.3. Idarucizumab
    6.4. Protamine
    6.5. Tranexamic Acid
    6.6. Vitamin K
    7. Anticoagulant Reversal Drugs Market, by Distribution
    7.1. Introduction
    7.2. Hospital Pharmacies
    7.3. Retail Pharmacies
    8. Americas Anticoagulant Reversal Drugs Market
    8.1. Introduction
    8.2. Argentina
    8.3. Brazil
    8.4. Canada
    8.5. Mexico
    8.6. United States
    9. Asia-Pacific Anticoagulant Reversal Drugs Market
    9.1. Introduction
    9.2. Australia
    9.3. China
    9.4. India
    9.5. Indonesia
    9.6. Japan
    9.7. Malaysia
    9.8. Philippines
    9.9. Singapore
    9.10. South Korea
    9.11. Taiwan
    9.12. Thailand
    9.13. Vietnam
    10. Europe, Middle East & Africa Anticoagulant Reversal Drugs Market
    10.1. Introduction
    10.2. Denmark
    10.3. Egypt
    10.4. Finland
    10.5. France
    10.6. Germany
    10.7. Israel
    10.8. Italy
    10.9. Netherlands
    10.10. Nigeria
    10.11. Norway
    10.12. Poland
    10.13. Qatar
    10.14. Russia
    10.15. Saudi Arabia
    10.16. South Africa
    10.17. Spain
    10.18. Sweden
    10.19. Switzerland
    10.20. Turkey
    10.21. United Arab Emirates
    10.22. United Kingdom
    11. Competitive Landscape
    11.1. FPNV Positioning Matrix
    11.2. Market Share Analysis, By Key Player
    11.3. Competitive Scenario Analysis, By Key Player
    12. Competitive Portfolio
    12.1. Key Company Profiles
    12.1.1. Alexion Pharmaceuticals Inc.
    12.1.2. AMAG Pharmaceuticals, Inc.
    12.1.3. Amneal Pharmaceuticals, Inc.
    12.1.4. AstraZeneca PLC
    12.1.5. Bausch Health Companies, Inc.
    12.1.6. BioVascular Inc.
    12.1.7. Boehringer Ingelheim GmbH
    12.1.8. Cadila Healthcare Limited
    12.1.9. CSL Limited
    12.1.10. Daiichi Sankyo Company, Limited
    12.1.11. Dr Reddy’s Laboratories Ltd,
    12.1.12. Eli Lilly and Company
    12.1.13. Fresenius Kabi AG
    12.1.14. Genentech, Inc.
    12.1.15. Hikma Pharmaceuticals PLC
    12.1.16. Octapharma AG
    12.1.17. Otsuka Pharmaceutical Co., Ltd.
    12.1.18. Pfizer, Inc.
    12.2. Key Product Portfolio
    13. Appendix
    13.1. Discussion Guide
    13.2. License & Pricing
    FIGURE 1. ANTICOAGULANT REVERSAL DRUGS MARKET RESEARCH PROCESS
    FIGURE 2. ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, 2023 VS 2030
    FIGURE 3. ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ANTICOAGULANT REVERSAL DRUGS MARKET DYNAMICS
    FIGURE 7. ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
    FIGURE 8. ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
    FIGURE 10. ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. AMERICAS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 12. AMERICAS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. UNITED STATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 14. UNITED STATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. ASIA-PACIFIC ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 16. ASIA-PACIFIC ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. ANTICOAGULANT REVERSAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 20. ANTICOAGULANT REVERSAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Request A Sample
    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us